---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-22-000137"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2022-02-18T23:59:59+00:00"
generated_at: "2026-06-27T06:36:47.829576+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma terminates acquisition negotiations for Canary Oncoceutics stake

## Summary
- Terminated all negotiations to acquire 95% of Canary Oncoceutics.
- LOI signed Nov 11, 2021, consideration: $1M cash + stock valued at pre-closing avg price.
- As of Feb 18, 2022, no definitive agreement reached; negotiations ended.

## SEC filing metadata
- accession: 0001607062-22-000137
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2022-02-18T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000137/0001607062-22-000137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706222000137/rgbp021822form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-22-000137
- JSON: https://secwatch.observer/filing/0001607062-22-000137.json
- Plain text: https://secwatch.observer/filing/0001607062-22-000137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.